Roche Diversifies With $105m-Plus Adheron Buy
This article was originally published in Scrip
Executive Summary
Roche will pay $105m up front and up to $475m in milestone fees to acquire Adheron Therapeutics in a deal that may help expand the Swiss big pharma portfolio in the company's key therapeutic areas outside of oncology.
You may also be interested in...
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.